Xeris Biopharma Holdings, Inc. XERS Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $83.13M-3.1% | $85.81M+15.4% | $74.38M+4.0% | $71.54M+19.0% | $60.12M0.0% | ||
| $10.57M-3.4% | $10.95M-0.4% | $11M-7.6% | $11.9M+36.3% | $8.73M-7.9% | ||
| $8.78M+11.5% | $7.87M+5.2% | $7.48M-7.1% | $8.06M+3.9% | $7.75M+27.3% | ||
| $53.14M+11.9% | $47.5M+2.2% | $46.46M+4.7% | $44.39M+0.9% | $44.02M+9.7% | ||
| $2.71M0.0% | $2.71M0.0% | $2.71M0.0% | $2.71M0.0% | $2.71M0.0% | ||
| $75.21M+8.9% | $69.03M+2.0% | $67.65M+0.9% | $67.06M+6.1% | $63.21M+8.2% | ||
| $7.92M-52.8% | $16.77M+149% | $6.73M+50.2% | $4.48M+245% | -$3.09M— | ||
| 9.5%-10.0pp | 19.5%+10.5pp | 9%+2.8pp | 6.3%+11.4pp | -5.1%-5.1pp | ||
| $6.88M-3.8% | $7.15M-1.6% | $7.27M-1.2% | $7.36M+0.7% | $7.31M-5.2% | ||
| $1.2M-17.7% | $1.46M+26.2% | $1.16M+22.2% | $948K-19.3% | $1.18M+29.1% | ||
| -$5.68M+0.2% | -$5.69M+6.8% | -$6.11M+4.7% | -$6.41M-4.6% | -$6.13M+9.7% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $2.23M-79.8% | $11.08M+1,684% | $621K+132% | -$1.93M+79.1% | -$9.22M-80.3% | ||
| 2.7%-10.2pp | 12.9%+12.1pp | 0.8%+3.5pp | -2.7%+12.6pp | -15.3%-6.8pp | ||
| $0.01-85.7% | $0.07— | $0.00+100% | -$0.01+83.3% | -$0.06-100% | ||
| $0.01-85.7% | $0.07— | $0.00+100% | -$0.01+83.3% | -$0.06-100% | ||
| 177.6M+2.8% | 172.7M-2.7% | 177.6M+11.4% | 159.5M+4.6% | 152.4M+3.9% | ||
| 170.5M+6.3% | 160.4M-2.0% | 163.6M+2.6% | 159.5M+4.6% | 152.4M+3.9% | ||
| $2.71M0.0% | $2.71M0.0% | $2.71M0.0% | $2.71M0.0% | $2.71M0.0% | ||
| $2.24M-79.8% | $11.08M+1,687% | $620K+132% | -$1.93M+79.1% | -$9.22M-80.0% | ||
| $1.2M-17.7% | $1.46M+26.2% | $1.16M+22.2% | $948K-19.3% | $1.18M+29.1% | ||
| $1K— | —— | -$1K-200% | $1K— | $0— | ||
| -$5.68M+0.2% | -$5.69M+6.8% | -$6.11M+4.7% | -$6.41M-4.6% | -$6.13M+9.7% | ||
| $83.13M-3.1% | $85.81M+15.4% | $74.38M+4.0% | $71.54M+19.0% | $60.12M0.0% | ||
| $7.92M-52.8% | $16.77M+149% | $6.73M+50.2% | $4.48M+245% | -$3.09M— | ||
| $8.25M-51.8% | $17.11M+142% | $7.07M+47.1% | $4.81M+273% | -$2.78M-987% | ||
| $8.25M-51.8% | $17.11M+142% | $7.07M+47.1% | $4.81M+273% | -$2.78M-987% | ||
| 9.9%-10.0pp | 19.9%+10.4pp | 9.5%+2.8pp | 6.7%+11.3pp | -4.6%-5.1pp | ||
| $7.92M-52.8% | $16.77M+149% | $6.73M+50.2% | $4.48M+245% | -$3.09M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Xeris Biopharma Holdings, Inc.'s revenue?
- Xeris Biopharma Holdings, Inc. (XERS) generated $314.9M in revenue over the trailing twelve months, up 41.5% year over year.
- Is Xeris Biopharma Holdings, Inc. profitable?
- Xeris Biopharma Holdings, Inc. reported $12.0M in net income over the trailing twelve months, a 3.8% net margin.
- What are Xeris Biopharma Holdings, Inc.'s profit margins?
- Gross margin is 85.9% and operating margin is 11.4%, with a 3.8% net margin.
- What is Xeris Biopharma Holdings, Inc.'s earnings per share?
- Xeris Biopharma Holdings, Inc.'s diluted EPS over the trailing twelve months is $0.07.
- Where does Xeris Biopharma Holdings, Inc.'s income statement data come from?
- Every line is extracted from Xeris Biopharma Holdings, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
